Eli Lilly is gaining on rival Novo Nordisk as its dual GIP/GLP-1 med tirzepatide—fresh off an approval pit stop in diabetes—slides into the FDA fast lane. Thursday, Lilly said the FDA flagged its drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results